Related Experiment Video
Updated: Sep 18, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
The PAH patient's perspective.
Daniel A Jeffery1, Wendy Gin-Sing2, Radwa Bedair3
1Morriston Cardiac Centre, Swansea Bay University Healthboard, Swansea, SA6 6NL, UK.
Pulmonary Arterial Hypertension associated with Congenital Heart Disease (PAH-CHD) presents significant challenges. Patients experience physical, emotional, and social impacts, affecting daily life and relationships.
Area of Science:
- Cardiology
- Pulmonology
- Patient Advocacy
Background:
- Pulmonary Hypertension (PH) is a serious condition in adults with congenital heart disease (CHD).
- Advances in CHD care allow patients to live longer, increasing the prevalence of PH-associated conditions.
- Pulmonary Arterial Hypertension associated with Congenital Heart Disease (PAH-CHD) presents unique challenges.
Purpose of the Study:
- To explore the multifaceted issues faced by patients living with PAH-CHD.
- To highlight the physical, emotional, social, and financial impacts of PAH-CHD.
- To provide patient perspectives on living with this complex condition.
Main Methods:
- Qualitative study involving interviews with two patients diagnosed with PAH-CHD.
- Exploration of patient experiences related to diagnosis, physical limitations, mental health, relationships, finances, and family planning.
Main Results:
- Patients with PAH-CHD encounter significant physical limitations and psychological distress, including depression and anxiety.
- The condition impacts social interactions, family dynamics, financial stability, and reproductive choices.
- Living with PAH-CHD necessitates comprehensive management strategies addressing diverse patient needs.
Conclusions:
- PAH-CHD imposes a substantial burden on patients' quality of life.
- Addressing the holistic needs of PAH-CHD patients is crucial for improving outcomes.
- Further research and patient support are essential for managing PAH-CHD effectively.
More Related Videos
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

